Categories: News

Cipla Health Strengthens ProlyteORS Portfolio with Launch of Masala Guava Flavour

MUMBAI, India, March 24, 2026 /PRNewswire/ — ProlyteORS, the W.H.O. recommended Oral Rehydration Salt (ORS) formulation from Cipla Health Limited, has announced the launch of the all-new Masala Guava flavour. Designed with Indian consumers at its core, the new variant brings together the proven efficacy of ORS with a taste rooted in Indian palates, making hydration not just effective but enjoyable delivering both science–backed relief and a familiar taste.

- Advertisement -

With this launch, Cipla Health reinforces its commitment to the oral rehydration category, where ProlyteORS has been a trusted name for years. The addition of the Masala Guava variant takes the portfolio to eleven flavours, all rooted in science, while evolving to meet the growing demand for hydration solutions that deliver both effectiveness and taste without compromise.

- Advertisement -

Commenting on the launch, Mr Shivam Puri, CEO and MD of Cipla Health, said, “Hydration is a fundamental part of maintaining overall health and wellbeing, particularly in a country like India where climatic conditions and active lifestyles can increase the risk of dehydration. ProlyteORS has always stood for science you can trust. With Masala Guava as an addition, it will be a reason for the consumers to reach for it every day and not just when they are unwell, but as a smarter hydration habit built into everyday life.

- Advertisement -

The new variant is the outcome of an extensive research and development process that balances strict formulation accuracy with consumer preferences. The flavour has undergone multiple rounds of testing to ensure it meets quality and efficacy benchmarks while delivering a taste that resonates with Indian consumers.

- Advertisement -

About Cipla Health Limited:

- Advertisement -

Cipla Health Limited, the fast-moving wellness goods (FMWG) arm of Cipla, was incorporated in 2015 with a vision to spearhead the wellness wave in India. Cipla Health has delivered rapid growth and today plays across a diverse portfolio of 20 brands with most key brands being No. 1 or No. 2 in their respective categories. The portfolio includes products in Pain Care (Omnigel), Smoking Cessation (Nicotex), Oral Rehydration Solutions (Prolyte), Medicated Ointments (Cipladine), Cough & Cold (Cofsils and Naselin), Multi Vitamins (Maxirich), Weight Gain (Endura Mass) and Personal Care (Rivela Dermascience, Cetafresh, Tugain Essentials and Astaberry).

- Advertisement -

Logo: https://mma.prnewswire.com/media/2658055/5581020/Cipla_Health_Logo.jpg

- Advertisement -

 

- Advertisement -

View original content:https://www.prnewswire.com/in/news-releases/cipla-health-strengthens-prolyteors-portfolio-with-launch-of-masala-guava-flavour-302723353.html

- Advertisement -

Recent Posts

Godrej Consumer Products Named World’s No.1 in Personal Products Sector on Dow Jones Best-in-Class Indices 2025

MUMBAI, India, March 24, 2026 /PRNewswire/ -- Godrej Consumer Products Limited (GCPL), a leading emerging…

2 hours ago

Furniture China Announces Landmark 2026 Edition: Where Design Creates Business

Organizers: CNFA and IM SinoexpoSHANGHAI, March 24, 2026 /PRNewswire/ -- Furniture China, Asia's premier furniture…

2 hours ago

SanSara Presents a Limited-Time Four-Hands Collaboration with Chef Sohan Singh of MICHELIN Bib Gourmand-Awarded RANG (Da Nang, Vietnam)

SINGAPORE, March 24, 2026 /PRNewswire/ -- SanSara at Grand Copthorne Waterfront Hotel Singapore unveils Two…

2 hours ago

ZEISS expands ophthalmic workflow portfolio in Canada with enhanced diagnostic, visualization and therapeutic solutions for precision eye care

Expanded treatment and visualization capabilities within posterior care workflows: ICGA for ZEISS CLARUS 700 offers…

3 hours ago

Zocdoc Launches The AI-Informed Patient Report, Revealing How Patient Use of AI Is Reshaping the Patient-Provider Relationship

New findings highlight rising—yet hidden—patient use of AI and surprisingly optimistic providers, pointing to an…

3 hours ago

Continuity Biosciences and Breakthrough T1D Collaborate to Advance NICHE Cell-Therapy Platform Toward First-in-Human Study

Collaboration supports IND-enabling development and a planned Phase 1/2a first-in-human clinical study in type 1…

3 hours ago